Clearline Capital LP Purchases Shares of 4,345 Humana Inc. (NYSE:HUM)

Clearline Capital LP acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 4,345 shares of the insurance provider's stock, valued at approximately $1,102,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HUM. Dodge & Cox raised its holdings in Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Vanguard Group Inc. increased its stake in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank acquired a new position in shares of Humana during the 4th quarter worth about $416,202,000. Pzena Investment Management LLC boosted its stake in Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the period. Finally, Boston Partners grew its holdings in Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock valued at $279,236,000 after buying an additional 893,637 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Down 1.5 %

NYSE:HUM traded down $3.68 on Friday, hitting $249.67. 1,087,102 shares of the stock were exchanged, compared to its average volume of 1,745,516. The stock has a market capitalization of $30.13 billion, a price-to-earnings ratio of 25.09, a P/E/G ratio of 2.05 and a beta of 0.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company's 50-day moving average price is $265.21 and its 200 day moving average price is $270.38.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business posted $7.23 earnings per share. On average, equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.42%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is 25.04%.

Analysts Set New Price Targets

HUM has been the topic of several research analyst reports. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Truist Financial increased their target price on shares of Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research note on Friday, April 11th. Oppenheimer upped their price target on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Finally, Robert W. Baird lifted their price objective on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Seventeen research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $287.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.